ERBB2 and breast carcinoma: On the other hand, many more patients bearing tumors with low to moderate levels of HER2, which are called HER2-low breast cancers (IHC 1+ or 2+ with ISH–), have not been considered candidates for conventional anti-HER2 therapies during the past two decades.